At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 158 enrolled
Drug / intervention
Revacept +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Revacept, an Inhibitor of Platelet Adhesion in Symptomatic Carotid Stenosis: A Phase II, Multicentre; Randomised, Dose-finding, Double-blind and Placebo Controlled Superiority Study With Parallel Groups
In Brief
A Phase 2 clinical trial evaluating Revacept and Placebo for Carotid Stenosis and 5 related conditions. Completed, enrolled 158 participants across 12 sites in 2 countries.
Detailed Summary
Patients suffering from symptomatic carotid artery stenosis, transient ischemic attacks (TIAs), amaurosis fugax or stroke receive either Revacept (single dose) plus antiplatelet monotherapy or monotherapy alone. Patients receive a single dose of trial medication by intravenous infusion for 20 minutes. Patients are followed up one and three days after treatment, at 3 months and by a telephone interview at 12 months.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCarotid Stenosis, Atherosclerosis, Stroke, Transient-ischaemic Attack, TIA, Amaurosis Fugax
CountriesGermany, United Kingdom
Collaborators--
Timeline
Phase 2CompletedFinished
20132014201520162017201820192020202120222023202420252026
First PostedJul 2012
Enrollment StartMar 2013
Primary CompletionOct 2018
Study CompletionSep 2019
TodayJul 2026
First PostedJul 20, 2012
Enrollment StartMar 8, 2013
Primary CompletionOct 5, 2018
Study CompletionSep 23, 2019
TodayJul 2, 2026
Enrollment to primary: 5.6 yearsPosted 14.0 years ago
Interventions
Revaceptdrug
single intravenous injection
Placebodrug
single intravenous injection